Objective: This is a network meta-analysis of nonvenous drugs used in randomized controlled trials (RCTs) for treatment of acute convulsive seizures and convulsive status epilepticus.
IV administration of benzodiazepines including lorazepam (LOR) and diazepam (DZP) is considered the first-line treatment for control of acute convulsive seizures and status epilepticus. 1,2 However, in many health care environments, establishing adequate venous access may be challenging, particularly in a convulsing patient. This difficulty may be augmented by lack of supplies, nonavailability of trained personnel at the point of care including out-of-hospital settings, collapsed peripheral veins, or malnutrition-related subcutaneous edema. Hence, nonvenous routes for administration of antiseizure medications to control acute convulsive seizures and convulsive status epilepticus have been explored, including sublingual (SL), rectal (PR), intranasal (IN), buccal (BC), and intramuscular (IM) routes. The present study is a systematic review of various nonvenous routes and drugs used in randomized controlled trials (RCTs) for treatment of acute convulsive seizures and convulsive status epilepticus along with a network meta-analysis (mixed or multiple treatment comparisons) of the data. 3 METHODS Literature search and data extraction. Structured search was conducted for RCTs of treatment of acute convulsive seizures or convulsive status epilepticus where at least one of the study arms was a nonvenous medication (table e-1 on the Neurology ® Web site at Neurology.org). All abstracts were screened by one of the authors (R.A.) and RCTs where the interventions seemed relevant were retained. Two authors (R.A. and H.K.) independently applied inclusion and exclusion criteria with disagreements being resolved by consensus. For eligible studies, one author (H.K.) extracted the data using a predesigned spreadsheet. Demographic and study methodology details were extracted for descriptive purposes. For each study arm, the number of participants, measured outcomes, and reported means (continuous variables) or proportions (dichotomous variables) were documented. Search results and study selection has been documented in a Preferred Reporting Items for Systematic reviews and Meta-Analyses diagram 4 (figure e-1).
Outcome measures. The dichotomous outcome measures included the proportion of participants with the following efficacy endpoints measured from the time of drug administration: seizure cessation within 10 minutes, seizure cessation within 5 minutes, and persistent seizure cessation for at least 1 hour. We included studies with only clinical and both clinical and EEG ascertainment of seizure termination for these outcomes. Since nonvenous routes find most utility in the out-of-hospital or resource-poor settings, clinical assessment of seizure activity was a representative endpoint. Further, the duration of continued seizure cessation after drug administration was reported differently by studies, with a minimum period of 1 hour. We have interpolated the reported proportions as representing participants who were seizure-free for at least 1 hour after receiving the study medication. Continuous outcomes included time from drug administration to termination of seizures, time to cessation of seizures after arrival to the health care facility, and time taken to initiate treatment. The time to initiate treatment has been reported differently in various studies, with respect to the initial timepoint (t 5 0), and includes time to delivery of the drug after randomization, opening of the envelope, arrival in the hospital, time to prepare and administer the drug, 5 or time from arrival of the nurse to medication administration. 6 The paucity of and variable definitions used for adverse events data in the RCTs makes it impossible to rigorously address differential tolerability and safety of nonvenous medications.
Data synthesis and statistical methods. Due to a variety of medications and routes used in different combinations with lack of sufficient studies for every possible pairwise comparison, a network meta-analysis was considered an appropriate methodology to synthesize the available data, and to provide an unbiased effect estimate taking into account both direct and indirect comparisons. 3, 7 We performed network meta-analyses within a Bayesian framework and summarized the treatment effects and their credible intervals (CrI). For pairwise comparisons, effect size was captured with a posterior median odds ratio (OR), which is derived from the distribution resulting from use of an assumed prior, mathematical model, and observed data. This Bayesian posterior distribution is non-normal and the appropriate measure is a median. Further, for pairwise comparisons with at least 4 available studies, we illustrated the relative strength of treatment effects using a Forest plot, and explored heterogeneity with I 2 and t 2 statistics. We also looked at publication bias using a funnel plot. The studies with missing data or disconnected from the respective outcome network were excluded from the meta-analysis. Instead, we have directly described the treatment effects from these studies.
We assumed a binomial distribution for dichotomous outcomes with use of logit-link function in the models, and lognormal distribution for continuous time-to-event outcomes. We calculated the probability of each route-drug combination being the most clinically effective for a given outcome, the second best, and so on, and provided their relative Bayesian hierarchical ranking using the methods described in Evidence Synthesis Technical Support Documents (Decision Support Unit, UK National Institute for Health and Clinical Excellence). 8 For fixed effects model, the common relative treatment effects were assumed for all studies. For random effects model, we assumed trial-specific relative treatment effects to come from a normal distribution with a common random effects variance for all treatment comparisons. We selected the best model based on the deviance information criteria, which provided measures of model fit. 9 The consistency between direct and indirect evidence was performed using node splitting methods. 10 To estimate the absolute treatment effects, we modeled the treatment effects of the baseline treatment independently using a fixed-effect model. 8 The posterior distributions of the absolute treatment effect of other treatments were obtained by synthesizing the posterior samples from both the baseline treatment model and the relative treatment effects model. The analyses were performed using Just Another Gibbs Sampler (JAGS 3.2.0), which simulates Bayesian hierarchical models using Markov chain Monte Carlo method. 11 Noninformative priors were used for all model parameters: uniform distribution for random effects variance and normal distributions with a zero mean and very large variance for all other parameters.
RESULTS

Characteristics of the included studies.
Twenty studies, published between 1997 and 2012, were eligible for the qualitative synthesis (figure e-1). 5, 6, 12229 Study participants ranged from newborns to 102 years of age, medications included LOR, DZP, midazolam (MDZ), and paraldehyde (PLD), and most studies were single-center (15/20) . Four studies were excluded due to the following: not connected to the networks for any of the outcomes (n 5 2) 16, 22 (figure 1), did not specify the number of participants allocated to each arm (n 5 1), 21 and did not report any of the meta-analysis outcomes (n 5 1). 13 Thus, 16 open-label studies were included in the quantitative synthesis, and 15/16 comprised only pediatric (#18 years) participants. The methods used for randomization were either suboptimal (5/16) or not reported (2/16) in some studies (table e-2).
Seizure cessation within 10 minutes of drug administration.
Eleven studies reported this outcome with 1 being disconnected from the network (figure 1A.a). 16, 22 The route-medication combinations reported by these studies included SL-LOR, IN-LOR, BC-MDZ, IN-MDZ, PR-DZP, IV-LOR, IM-PLD, and IV-DZP (table e-3). Out of the nonvenous route-drug combinations, IN-MDZ was the best (weighted event rate [WER] 90.4%) followed by BC-MDZ (80.7%) and PR-DZP (69.9%). On pairwise comparisons, IN-MDZ was superior to PR-DZP (OR 4.420, 95% CrI 1.687-13.201). Also, BC-MDZ was superior to PR-DZP (OR 1.822, 95% CrI 1.308-2.53), whereas SL-LOR was inferior to all other medications (table 1) . Studies for IM-MDZ and IV-LOR were disconnected from the network, rendering this outcome uninformative for these medications. Although IN-LOR was disconnected from the network, the proportion of patients meeting the above endpoint was 78.8% (pooled event rate).
Since 4 studies compared BC-MDZ with PR-MDZ for this outcome, we performed a nested head-to-head meta-analysis. BC-MDZ was superior to PR-DZP (random effects OR 1.78, 95% confidence interval [CI] 1.12-2.82) with trivial heterogeneity in the evidence (I 2 5 38.9%, figure 2). The funnel plot did not reveal any significant impact on the conclusion about relative treatment effect, even when a "pseudostudy" was added using trim-and-fill method to adjust for funnel plot asymmetry 30 (figure 2). Seizure cessation within 5 minutes of drug administration.
This outcome was reported by only 3 studies, 1 being disconnected from the network ( figure 1A.b ). 12 The route-drug combinations analyzed were SL-LOR, BC-MDZ, IM-MDZ, PR-DZP, and IV-DZP ( A majority of studies reported this outcome (n 5 14). However, 2 studies were disconnected from the network ( figure 1B.a) , 16, 22 3 others had missing data points, 15, 21, 23 and 1 study had censored observations at 10 minutes. 20 The (table 1) . Of the 7 studies including IN-MDZ, none reported using atomizers: 3 studies used syringes (not reported whether atomizers were attached), 21,26,28 1 used nasal dropper, 5 and the others did not mention their method of administration. 14, 17, 27 Hence, these results for IN-MDZ should be interpreted carefully, since there is some evidence for altered absorption kinetics when an atomizer is used for nasal delivery. 31 The Bayesian hierarchical analysis also showed BC-MDZ to be second most efficacious nonvenous medication for some of these outcomes (table 3) . Notably, whereas the time to initiate treatment was not significantly different for IM-MDZ, BC-MDZ, and IN-MDZ, these drugs differed regarding time to seizure termination such that IM-MDZ and IN-MDZ were not statistically different, but both were superior to BC-MDZ in pairwise comparisons (table 2) . These are important clinical considerations when prescribing a rescue medication for out-ofhospital use.
Guidelines for management of acute convulsive seizures or convulsive status epilepticus recommend IV-LOR as the first drug. [32] [33] [34] The safety and efficacy of IV-LOR has been demonstrated in multiple settings. 1, 16, 35 In the Veterans Affairs study, 1 IV-LOR successfully stopped all clinical and electrical seizure activity within 20 minutes of administration with no recurrence for 60 minutes in 67% of patients (n 5 100) with overt status epilepticus. 1 Recently, among children aged 3 months to 18 years, IV-LOR (97/133, 72.9%) was not found to be superior to IV-DZP (101/140, 72.1%) for cessation of convulsive status epilepticus for 10 minutes without recurrence within 30 minutes (absolute difference 0.8%, 95% CI 211.4% to 9.8%). 2 While these IV medications are suitable for wellequipped emergency rooms adept at rapid vascular access and well-trained emergency response teams, there is a lack of standard recommendations regarding nonvenous route-drug combinations. 36, 37 In the United States, PR-DZP is perhaps the most commonly prescribed nonvenous medication for use as a caregiver-administered rescue treatment of acute convulsive seizures. However, our analyses showed that it achieves seizure cessation within 10 minutes in only ;70% of patients, with sustained seizure cessation for $1 hour in only ;55% of patients, being inferior to IN-MDZ and BC-MDZ (table 1) . PR-DZP was also inferior to other nonvenous medications regarding time for seizure termination and time to initiate treatment (table 2). In the community, particularly in adolescents, rectal medication may be socially embarrassing and potentially stigmatizing.
The safety and efficacy of IM-MDZ is also attested by Class I evidence from the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) study. 13 After prehospital treatment of status epilepticus by paramedics, seizures were absent without the rescue medication on arrival to the emergency department in 329/448 (73.4%) of subjects in the IM-MDZ group compared to 282/445 (63.4%) in the IV-LOR group (absolute difference 10%, 95% CI 4.0-16.1, p , 0.001). While the median time to administration was significantly shorter for IM-MDZ compared to IV-LOR (1.2 vs 4.8 minutes), the termination of seizures took longer with the former (3.3 vs 1.6 minutes). 13 For IM-MDZ, these outcomes are similar to the pooled estimates obtained in the present study (0.8 and 2.2 minutes, respectively, table 2). Adverse event rates were similar in both groups. These results together with our metaanalyses argue strongly to consider IM-MDZ as the nonvenous drug of choice for treatment of acute convulsive seizures and convulsive status epilepticus, with IN-MDZ as an alternative where IM injection is not feasible.
The limitations of this study result from evidence gaps including paucity of high-quality RCTs, variability in study populations and drug dosages, and small networks with variably disconnected studies. The meta-analysis can accommodate but cannot reconcile the scant source data. Also, all studies included in the quantitative synthesis were open-label. Certain nonvenous routes used in acute care settings, like intraosseous, are not represented due to lack of RCTs. Hence, this meta-analysis' conclusions will have the same or slightly higher level of evidence than these source RCTs. Further, in network analysis, indirect comparisons may be biased if the factors that differ across trials are effect modifiers of the response. Some studies were limited to convulsive status epilepticus while others also included relatively brief seizures. Individual studies excluded patients with prior administration of benzodiazepines, 12, 17 any antiseizure medications, 14, 16, 26 signs of upper respiratory infection, 14 prior IV access, 18, 28 or certain etiologies of acute symptomatic seizures. 19 Although the doses of PR-DZP (0.3-0.5 mg/kg) and BC-MDZ (0.2-0.5 mg/kg, fixed 10 mg) varied across studies, 6, 19, 20 the doses of IM-MDZ (0.2 mg/kg) and IN-MDZ (0.2 mg/kg) were fairly consistent. 19, 20, 23, 29 Also, studies have measured the time to initiate treatment differently in terms of initial reference timepoint, which can potentially bias the results. For example, the outcome can be overestimated if measured from the time of arrival in the hospital compared to if measured from time of randomization. Finally, these results only incorporated efficacy and not safety of the analyzed medications, due to variability in defining and reporting adverse events across studies. Hence, the present results should be used in conjunction with factors specific to the individual patient and the health care system. In many health care environments, nonvenous treatment of acute convulsive seizures is highly desirable. This meta-analysis together with the RAMPART study 13 should encourage health care providers to consider IM-MDZ as an acceptable first choice nonvenous medication, when the IM route is feasible. IM administration may be most appropriate when used by paramedics in the field or in the hospital before IV access is established. Future availability of inexpensive, easy-touse autoinjectors may facilitate IM administration even by nonmedical personnel in out-of-hospital settings. When the IM route is not feasible, IN-MDZ is an easily administered alternative, particularly for out-of-hospital use by nonmedical personnel. Wider use of atomizers may further improve and promote IN administration. Nonvenous formulations for treatment of seizure emergencies currently being developed are further expected to provide effective and user-friendly alternatives. 38 Among the various route-drug combinations used in RCTs, IM-MDZ was the most efficacious nonvenous medication for time to seizure termination after administration, and time to initiate treatment. IN-MDZ was the most efficacious nonvenous medication regarding seizure cessation within 10 minutes of administration and sustained seizure cessation for at least 1 hour. The results of this study support a practice change towards wider use of IM-MDZ and IN-MDZ in appropriate settings.
